MMMd David J. Mysels

Md David J. Mysels

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Md David J. Mysels has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Maria A. Sullivan

    Columbia University Medical Center/New York State Psychiatric Institute Division of Substance Abuse Research

    2 shared publications
  • Frances R. Levin

    Columbia University Medical Center/New York State Psychiatric Institute Division of Substance Abuse Research

    1 shared publication
  • Ileana Benga

    1 shared publication
  • Suzanne K. Vosburg

    Columbia University Medical Center/New York State Psychiatric Institute Division of Substance Abuse Research

    1 shared publication

Latest Publications

  • Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients

    by Md David J. Mysels, Suzanne K. Vosburg, Ileana Benga, Frances R. Levin, Maria A. Sullivan

    Background: μ-Opiate receptor agonism has been associated with weight gain, whereas μ-antagonists have been associated with weight neutrality, or even weight loss.Aim: This study examined the course of weight changes in opiate-dependent patients over the first 6 months of treatment in methadone (agonist) versus naltrexone (antagonist) maintenance.Design: A retrospective chart review was conducted on 36 opiate-dependent patients maintained on methadone (n = 16) or naltrexone (n = 20). Outcome measures and analyses: The primary outcome measure was change in body weight from baseline to 3 months and 6 months into treatment. Analysis of variance was used to compare mean weights between the methadone- and naltrexone-maintained patients. Secondarily, mean percent weight changes from baseline to 3 months and from baseline to 6 months into treatment were compared using Student’s t-test.Results: There was no difference between weight at baseline, 3 months, or 6 months into treatment between the two treatment groups. Furthermore, there was also no difference between the two groups regarding percent weight change from baseline to 3 months or baseline to 6 months. At 3 months, n = 16 methadone patients had a mean weight increase of 1.86 percent (standard deviation [SD] = 7.22 percent) when compared with n = 20 Behavioral Naltrexone Therapy (BNT) patients with an increase of 4.63 percent (SD = 6.49 percent). At 6 months, n = 16 methadone patients had a mean weight increase relative to baseline of 3.67 percent (SD = 9.52 percent) when compared with n = 20 BNT patients, who demonstrated a mean increase of 6.69 percent (SD = 7.56 percent). No association was found between baseline weight, defined as “low” or “high” relative to group medians, and percent gain within and between treatment groups.Conclusions: This study did not detect a statistically different course of weight gain between methadone and naltrexone maintenance treatment for opiate-dependent patients.


  • The relationship between opioid and sugar intake: Review of evidence and clinical applications

    by Md David J. Mysels, Maria A. Sullivan

    Opioid dependence poses significant public health risks arising from associated morbidity and mortality caused by accidents, infectious diseases, and social ramifications of crime and unemployment, among other complications. Opioid use, acute and chronic, is also associated with weight gain, glycemic dysregulation, and dental pathology. The literature supporting the connection between opiate use and development of preference for sweet tastes is reviewed, and further association with dental pathology, weight gain, and loss of glycemic control are considered. Additionally, the impact of sweet tastes on the endogenous opioid system, as pertaining to analgesia, is also discussed. The authors discuss the clinical implications in relation to the aforementioned conditions while treating the opiate-dependent patient.


  • The Kappa‐Opiate Receptor Impacts the Pathophysiology and Behavior of Substance Use

    by David Mysels

    There is increasing evidence that the kappa‐opiate receptor, in addition to the mu‐opiate receptor, plays an important role in substance use pathophysiology and behavior. As dopamine activity is upregulated through chronic substance use, kappa receptor activity, mediated through the peptide dynorphin, is upregulated in parallel. Dynorphin causes dysphoria and decreased locomotion, and the upregulation of its activity on the kappa receptor likely dampens the excitation caused by increased dopaminergic activity. This feedback mechanism may have significant clinical implications for treating drug dependent patients in various stages of their pathology.